Breast Cancer Coverage from Every Angle

Recent News

Proton-Based Radiotherapy After Breast-Conserving Surgery
S-1 Plus Standard Endocrine Therapy After Surgery for Breast Cancer
Palbociclib Plus Endocrine Therapy Versus Chemotherapy: Outcomes in Metastatic Breast Cancer
Predicting Relapse in Early-Stage Breast Cancer Using ‘Liquid Biopsy’
Pertuzumab Plus Standard Treatment in HER2-Positive Early Breast Cancer
KEYNOTE-522 in Triple-Negative Breast Cancer: Pathologic Complete Response Rates With Pembrolizumab
Oral Paclitaxel With P-Glycoprotein Pump Inhibitor in Metastatic Breast Cancer
Using ctDNA to Predict Recurrence of Triple-Negative Breast Cancer
Accelerated Approval Granted by FDA for [Fam]-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer
FDA Grants Breakthrough Therapy Designation to Tucatinib in Advanced HER2-Positive Breast Cancer
SABCS 2019: Margetuximab Versus Trastuzumab in HER2-Positive Metastatic Breast Cancer
SABCS 2019: Novel Antibody-Drug Conjugate in HER2-Positive Metastatic Breast Cancer
SABCS 2019: Tucatinib-Based Therapy for HER2-Positive Metastatic Breast Cancer
FDA Approves Companion Diagnostic for Alpelisib in PIK3CA-Mutated Metastatic Breast Cancer
Potential Role of E-cadherin in Breast Cancer Metastasis
How Does HIV Infection Affect Survival in Patients With Breast Cancer?
Novel Approach to Targeting Metastatic Breast Cancer Through Sonoporation
Updated USPSTF Recommendation on Medication Use to Reduce Breast Cancer Risk
NCRI Conference: Ongoing Study of Blood Test for Early Detection of Breast Cancer
KEYNOTE-119 Trial of Pembrolizumab Versus Chemotherapy for Triple-Negative Breast Cancer
Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
FDA Grants Priority Review for Trastuzumab Deruxtecan in Metastatic Breast Cancer
FDA Recommends Warnings on Labeling for Breast Implants
ESMO 2019: Adding Veliparib to Chemotherapy for BRCA-Mutated Breast Cancer
ASCO Breakthrough 2019: Genetic Predictors of Breast Cancer Recurrence After Radiation Therapy
ESMO 2019: Survival Benefit Reported With CDK4/6 Inhibitor in Advanced Breast Cancer
Higher Exposure to Toxic Metals May Equal Higher Breast Cancer Risk
Can Artificial Intelligence Improve Accuracy of Digital Breast Tomosynthesis?
ESMO 2019: Improved Overall Survival With Abemaciclib/Fulvestrant in Advanced Breast Cancer
Quality Care 2019: Web-Based Survey of Patient Engagement Among Breast Cancer Survivors
Quality Care 2019: Chemotherapy Decisions of Older Women With Early-Stage Breast Cancer
Quality Care 2019: Pilot Program Focuses on Improving Breast Cancer Staging Data Entries
ASTRO 2019: Postmastectomy Radiation Therapy for HER2-Positive Breast Cancer
FDA Issues Warning About Lung Inflammation and Use of CDK4/6 Inhibitors
USPSTF Recommendation Updates for Women With BRCA-Related Cancer
Quality Care 2019: Impact of Breast Cancer on Key Support Person’s Employment
Is Red Meat Consumption Linked to Breast Cancer Risk?
Two-Drug Combination Targets Resistance in Cancer
FDA Draft Guidance Encourages Inclusion of Male Patients in Breast Cancer Clinical Trials
Comparing First-Line Treatments in Triple-Negative Breast Cancer
Real-World Data on Palbociclib Plus Endocrine Therapy in Men With Advanced Breast Cancer
IMpassion130 Trial: Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer
Is Soy Intake Related to Bone Fractures for Breast Cancer Survivors?
FDA Requests Manufacturer Recall of Certain Textured Breast Implants

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.